Erin Cooksey, MD
Family Medicine · Anderson, SCNPI 1376675074
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,051 of the $10,132 with a category attached, or 79.5%. 39 manufacturers reported payments, led by AbbVie at 26.8% of the total. Reporting peaked in 2019 at $3,936 and has fallen 64.4% since, to $1,400 in 2025. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$1K
- Novo Nordisk AS$952
- Novo Nordisk$876
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$426
- Novartis$403
- plus $4K from 33 others
Across 465 payments — averaging $2500.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$424K
- Novo Nordisk AS$417K
- Kowa Research Institute, Inc.$80K
- Rhythm Pharmaceuticals, Inc.$74K
- Valneva Austria GmbH$67K
- Sanofi US Services Inc.$35K
- plus $66K from 5 others
What the payments were for
- Travel & lodging$2,05420%
- Food & beverage$8,05179%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $2,719 |
| AstraZeneca | 54 | $1,044 |
| Novo Nordisk AS | 4 | $952 |
| Novo Nordisk | 80 | $876 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $426 |
| Novartis | 27 | $403 |
| Bayer | 48 | $393 |
| Insulet Corporation | 5 | $322 |
| Boehringer Ingelheim | 25 | $313 |
| Johnson & Johnson | 20 | $303 |
| Amgen | 19 | $277 |
| Abbott | 15 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $218 |
| GSK | 13 | $188 |
| Lilly USA, LLC | 7 | $184 |
| Astellas Pharma US Inc | 8 | $135 |
| Boston Scientific | 5 | $107 |
| Lundbeck LLC | 4 | $82 |
| Eisai Inc. | 4 | $76 |
| Kowa Pharmaceuticals America, Inc. | 6 | $74 |
| Pfizer | 5 | $72 |
| Sanofi-aventis U.S. LLC | 5 | $70 |
| Esperion Therapeutics, Inc. | 5 | $69 |
| E.r. Squibb & Sons, L.L.C. | 5 | $62 |
| Medtronic | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Merck | 4 | $60 |
| Edwards Lifesciences | 3 | $60 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Ardelyx, Inc. | 2 | $33 |
| Shield Therapeutics Inc | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Resmed Corp | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,132 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $239,796 |
| FarxigaDapagliflozin Propanediol | 141 | $142,930 |
| MounjaroTirzepatide | 84 | $98,488 |
| EliquisApixaban | 116 | $94,665 |
| TrulicityDulaglutide | 63 | $84,987 |
| JanuviaSitagliptin Phosphate | 101 | $77,106 |
| JardianceEmpagliflozin | 56 | $56,665 |
| RybelsusSemaglutide | 37 | $54,704 |
| XifaxanRifaximin | 12 | $44,007 |
| CreonLipase/Protease/Amylase | 35 | $37,311 |
| XareltoRivaroxaban | 47 | $36,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $33,638 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $30,723 |
| LinzessLinaclotide | 38 | $28,947 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $27,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $876 | $294,500225 claims |
| Lilly USA, LLCMounjaro, Trulicity | $184 | $183,475147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,044 | $179,831195 claims |
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat, Synjardy Xr, Stiolto Respimat | $313 | $116,700128 claims |
| PfizerEliquis | $72 | $94,665116 claims |
| MerckJanuvia | $60 | $77,106101 claims |
| AbbVieCreon, Linzess, Synthroid | $2,719 | $75,846198 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $188 | $52,28482 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $426 | $44,00712 claims |
| Johnson & JohnsonXarelto | $303 | $36,58547 claims |
| Astellas Pharma US IncMyrbetriq | $135 | $27,00337 claims |
| NovartisEntresto | $403 | $17,82214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Anderson
- Joseph AbrahamAnderson$14K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.